AR119471A1 - Compuestos agonistas de gipr - Google Patents

Compuestos agonistas de gipr

Info

Publication number
AR119471A1
AR119471A1 ARP200102070A ARP200102070A AR119471A1 AR 119471 A1 AR119471 A1 AR 119471A1 AR P200102070 A ARP200102070 A AR P200102070A AR P200102070 A ARP200102070 A AR P200102070A AR 119471 A1 AR119471 A1 AR 119471A1
Authority
AR
Argentina
Prior art keywords
compounds
agonist compounds
useful
treatment
gip
Prior art date
Application number
ARP200102070A
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Andrea Renee Geiser
Lili Guo
Samantha Grace Lyons Keyser
John Lee
Honghcang Qu
William Christopher Roell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR119471A1 publication Critical patent/AR119471A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a compuestos que tienen actividad en el receptor de polipéptido insulinotrópico dependiente de glucosa (GIP) humano. La presente se refiere además a compuestos que tienen una duración de acción prolongada en el receptor de GIP. Tales compuestos pueden ser útiles en el tratamiento de la diabetes, que incluye diabetes mellitus tipo 2 (“T2DM”). Además, los compuestos pueden ser útiles en el tratamiento de la obesidad.
ARP200102070A 2019-08-01 2020-07-23 Compuestos agonistas de gipr AR119471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962881685P 2019-08-01 2019-08-01

Publications (1)

Publication Number Publication Date
AR119471A1 true AR119471A1 (es) 2021-12-22

Family

ID=72145469

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102070A AR119471A1 (es) 2019-08-01 2020-07-23 Compuestos agonistas de gipr

Country Status (20)

Country Link
US (2) US11254721B2 (es)
EP (1) EP4007593A1 (es)
JP (2) JP7230272B2 (es)
KR (1) KR20220028007A (es)
CN (1) CN114206915A (es)
AR (1) AR119471A1 (es)
AU (1) AU2020322784A1 (es)
BR (1) BR112022000027A2 (es)
CA (1) CA3145608A1 (es)
CL (1) CL2022000140A1 (es)
CO (1) CO2022000759A2 (es)
CR (1) CR20220020A (es)
DO (1) DOP2022000025A (es)
EC (1) ECSP22008098A (es)
IL (1) IL289463A (es)
JO (1) JOP20220024A1 (es)
MX (1) MX2022001137A (es)
PE (1) PE20220938A1 (es)
TW (1) TWI764209B (es)
WO (1) WO2021021877A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
AR124295A1 (es) * 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
WO2024080650A1 (ko) * 2022-10-12 2024-04-18 서울대학교병원 Gipr 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
CN116410298B (zh) * 2023-06-06 2023-08-11 诺博泰科(成都)生物科技有限公司 一种三激动多肽化合物及其盐、药用组合物、药剂和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102184241B1 (ko) 2012-05-03 2020-12-01 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법
RU2716985C2 (ru) * 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2020067575A1 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
JP2022503793A (ja) 2018-09-24 2022-01-12 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr

Also Published As

Publication number Publication date
CN114206915A (zh) 2022-03-18
KR20220028007A (ko) 2022-03-08
JP7230272B2 (ja) 2023-02-28
CA3145608A1 (en) 2021-02-04
TWI764209B (zh) 2022-05-11
CL2022000140A1 (es) 2022-09-30
ECSP22008098A (es) 2022-03-31
US11897926B2 (en) 2024-02-13
MX2022001137A (es) 2022-02-16
JP2022544061A (ja) 2022-10-17
DOP2022000025A (es) 2022-03-15
BR112022000027A2 (pt) 2022-05-24
JP2023062068A (ja) 2023-05-02
US11254721B2 (en) 2022-02-22
AU2020322784A1 (en) 2022-02-03
CO2022000759A2 (es) 2022-02-07
PE20220938A1 (es) 2022-05-31
WO2021021877A1 (en) 2021-02-04
TW202126680A (zh) 2021-07-16
JOP20220024A1 (ar) 2023-01-30
CR20220020A (es) 2022-02-14
EP4007593A1 (en) 2022-06-08
US20220127315A1 (en) 2022-04-28
US20210032299A1 (en) 2021-02-04
IL289463A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
AR119471A1 (es) Compuestos agonistas de gipr
ECSP21004913A (es) Compuestos coagonistas de gip/glp1
UA118239C2 (uk) Сполука-коагоніст gip і glp-1
DOP2017000102A (es) Coagonistas de los receptores de glucagón y de glp-1
BR112021023923A2 (pt) Agonistas de receptor de peptídeo 1 similares a glucagon
CL2017003185A1 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
EA202091284A1 (ru) Аналоги инкретина и их применение
AR099977A1 (es) Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
PE20151770A1 (es) Compuesto peptidico
EA201001801A1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
EA201291234A1 (ru) Аналоги глюкагона
EA201170302A1 (ru) Процессированные аналоги глюкозозависимого инсулинотропного полипетида
AR121093A1 (es) Compuestos coagonistas de gip / glp1
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
JOP20220153A1 (ar) نظائر الإنكرتين واستخداماتها
ECSP17032341A (es) Coagonistas de los receptores de glucagón y de glp-1
MX2022007928A (es) Co-agonistas de olefina engrapados de los receptores de glucagon y glp-1.